Santhera Pharmaceuticals

Founded in 2004 and located in Liestal, Switzerland, and with subsidiaries in Germany, the UK, Italy, the Netherlands, Liechtenstein, the US and Canada, Santhera Pharmaceuticals is a speciality pharmaceutical company committed to developing medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.

Santhera’s lead candidate, idebenone (marketed as Raxone® in Europe, and Catena® in other regions) is currently being developed in three conditions: Leber’s Hereditary Optic Neuropathy (LHON), a hereditary form of blindness; Duchenne Muscular Dystrophy (DMD), the most common form of muscular dystrophy and primary progressive Multiple Sclerosis (ppMS), a type of MS in which disease progression is steady and without remissions. These are all orphan indications without satisfactory treatment options.

Waypoint's investment with the company dates to 2008.